Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
de Bono, J. [1 ,2 ]
Bracarda, S. [3 ,4 ]
Chi, K. [5 ]
Massard, C. [6 ]
Olmos Hidalgo, D. [7 ]
Sandhu, S. [8 ]
Sternberg, C. N. [9 ]
Gendreau, S. [10 ]
Xu, N. [11 ]
Baney, T. [12 ]
Maslyar, D. [13 ]
Sweeney, C. J. [14 ]
机构：
[1] Inst Canc Res, Div Clin Studies & Expt Med, London, England
[2] Royal Marsden Hosp, London, England
[3] ITT, Azienda USL Toscana Sud Est, Dept Oncol, Med Oncol, Arezzo, Italy
[4] Osped San Donato, Arezzo, Italy
[5] BC Canc Agcy, Clin Trials Unit, Vancouver, BC, Canada
[6] Inst Gustave Roussy, Early Drug Dev Dept, Villejuif, France
[7] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid, Spain
[8] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[9] San Camillo & Forlanini Hosp, Dept Oncol, Rome, Italy
[10] Genentech Inc, Late Stage Biomarker Dev, San Francisco, CA 94080 USA
[11] Genentech Inc, Biostat Oncol Solid Tumor, San Francisco, CA 94080 USA
[12] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[13] Genentech Inc, Prod Dev Clin Oncol, San Francisco, CA 94080 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
834TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [22] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    Pili, Roberto
    Haggman, Michael
    Stadler, Walter M.
    Gingrich, Jeffrey R.
    Assikis, Vasileios J.
    Bjork, Anders
    Nordle, Orjan
    Forsberg, Goran
    Carducci, Michael A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4022 - 4028
  • [24] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
    Clarke, Noel W.
    Armstrong, Andrew J.
    Oya, Mototsugu
    Shore, Neal
    Procopio, Giuseppe
    Guedes, Joao Daniel
    Arslan, Cagatay
    Mehra, Niven
    Parnis, Francis
    Brown, Emma
    Schlurmann, Friederike
    Joung, Jae Young
    Sugimoto, Mikio
    Sartor, Oliver
    Poehlein, Christian
    McGuinness, David
    Degboe, Arnold
    Saad, Fred
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 394 - 406
  • [26] A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide
    Denmeade, S.
    Antonarakis, E.
    Paller, C.
    Wang, H.
    Benjamin, T.
    Drake, C.
    Carducci, M.
    Eisenberger, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S15 - S15
  • [27] A PHASE II STUDY (PERSEUS) OF TWO DOSES OF EMD 525797 (DI17E6) IN PATIENTS (PTS) WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Miller, K.
    Hussain, M.
    Mordenti, G.
    Lannert, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 317 - 318
  • [28] Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA plus P).
    Gotto, Geoffrey
    Fradet, Vincent
    Drachenberg, Darrel
    Sabbagh, Robert
    Rendon, Ricardo A.
    Shayegan, Bobby
    Danielson, Brita Lavender
    Casey, Richard
    Chan, Katherine
    Camacho, Fernando
    Zardan, Anousheh
    Hew, Huong
    Feifer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL - MCRPC): A Movember funded multicenter, randomized, controlled phase III study.
    Saad, Fred
    Kenfield, Stacey A.
    Chan, June M.
    Hart, Nicolas H.
    Courneya, Kerry S.
    Catto, James
    Finn, Stephen P.
    Greenwood, Rosemary
    Hughes, Daniel C.
    Mucci, Lorelei A.
    Plymate, Stephen R.
    Pollak, Michael N.
    Praet, Stephan F. E.
    Russell, Aaron P.
    Guinan, Emer M.
    Van Blarigan, Erin
    Casey, Orla
    Buzza, Mark
    Ryan, Charles J.
    Newton, Robert Usher
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).
    Colomba, Emeline
    Jonas, Sarah Flora
    Eymard, Jean-Christophe
    Delva, Remy
    Brachet, Pierre-Emmanuel
    Neuzillet, Yann
    Penel, Nicolas
    Roubaud, Guilhem
    Bompas, Emmanuelle
    Mahammedi, Hakim
    Longo, Raffaele
    Helissey, Carole
    Barthelemy, Philippe
    Borchiellini, Delphine
    Hasbini, Ali
    Priou, Franck
    Saldana, Carolina
    Voog, Eric
    Foulon, Stephanie
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345